Ibio Inc

NYSE American:IBIOUnited States

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Contact Information

Headquarters

8800 HSC PkwyBRYAN, TX, United States 77807

Phone

979-446-0027

Fax

302-636-5454

Executives

Independent Chairman of the Board

William Clark

Chief Executive Officer, Chief Scientific Officer, Director

Martin Brenner

Interim Chief Financial Officer

Felipe Duran

Chief Legal Counsel

Marc Banjak

Independent Director

Alexandra Kropotova